argenx SE(ARGX)Earnings, Financials & Key Ratios
ARGX•NASDAQ
44.7× P/E·Price updated Jun 19, 2026
Aboutargenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.Show more
- Revenue$4.15B+89.6%
- EBITDA$1.08B+26335.0%
- Net Income$1.29B+55.1%
- EPS (Diluted)19.63+53.6%
- Gross Margin89.15%-0.5%
- EBITDA Margin26.07%+13936.4%
- Operating Margin25.39%+2668.1%
- Net Margin31.11%-18.2%
- ROE20.15%+16.1%
ARGX Key Insights
argenx SE (ARGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓FCF machine: 20.3% free cash flow margin
- ✓Strong 5Y sales CAGR of 151.5%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ARGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARGX Price & Volume
argenx SE (ARGX) stock price & volume — 10-year historical chart
Loading chart...
ARGX Growth Metrics
argenx SE (ARGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years88.09%
5 Years151.54%
3 Years116.24%
TTM174.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM253.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM279.75%
Return on Capital
10 Years-15.38%
5 Years-7.72%
3 Years1.23%
Last Year16.36%
ARGX Recent Earnings
argenx SE (ARGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (71%)●Beat Revenue 5/12 qtrs (83%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$5.90-5.9%
$6.27
Rev
$2.4B+66.0%
$1.4B
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$8.02+48.2%
$5.41
Rev
$2.4B+79.6%
$1.3B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$5.18+18.5%
$4.37
Rev
$948M-25.7%
$1.3B
Q2 2025
May 8, 2025Metric
Actual
Est
EPS
$2.58+163.3%
$0.98
Rev
$1.3B+56.2%
$862M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $5.90vs $6.27-5.9% | $2.4Bvs $1.4B+66.0% |
| Q1 2026 | Feb 26, 2026 | $8.02vs $5.41+48.2% | $2.4Bvs $1.3B+79.6% |
| Q4 2025 | Oct 30, 2025 | $5.18vs $4.37+18.5% | $948Mvs $1.3B-25.7% |
| Q2 2025 | May 8, 2025 | $2.58vs $0.98+163.3% | $1.3Bvs $862M+56.2% |
Based on last 12 quarters of dataView full earnings history →
ARGX Peer Comparison
argenx SE (ARGX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 |
Compare ARGX vs Peers
argenx SE (ARGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARGX Income Statement
argenx SE (ARGX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 43.69M | 24.57M | 78.46M | 41.24M | 497.28M | 410.75M | 1.23B | 2.19B | 4.15B |
Revenue Growth % | 182.33% | -43.75% | 219.3% | -47.44% | 1105.72% | -17.4% | 198.56% | 78.6% | 89.64% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 29.43M | 117.83M | 227.29M | 450.67M |
COGS % of Revenue | - | - | - | - | - | 7.17% | 9.61% | 10.38% | 10.85% |
Gross Profit | 43.69M▲ 0% | 24.57M▼ 43.8% | 78.46M▲ 219.3% | 41.24M▼ 47.4% | 497.28M▲ 1105.7% | 381.31M▼ 23.3% | 1.11B▲ 190.7% | 1.96B▲ 77.1% | 3.7B▲ 88.6% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 92.83% | 90.39% | 89.62% | 89.15% |
Gross Profit Growth % | 182.33% | -43.75% | 219.3% | -47.44% | 1105.72% | -23.32% | 190.7% | 77.08% | 88.64% |
Operating Expenses | 71.2M | 118.2M | 277.35M | 518.86M | 846.02M | 1.1B | 1.53B | 1.98B | 2.65B |
OpEx % of Revenue | 162.98% | 481.02% | 353.49% | 1258.06% | 170.13% | 268.21% | 125.05% | 90.61% | 63.76% |
Selling, General & Admin | 14.93M | 31.42M | 72.15M | 170.55M | 305.52M | 469.92M | 709.54M | 1.06B | 1.36B |
SG&A % of Revenue | 34.18% | 127.88% | 91.95% | 413.53% | 61.44% | 114.41% | 57.86% | 48.18% | 32.74% |
Research & Development | 62.07M | 95.64M | 220.77M | 370.49M | 580.52M | 663.37M | 859.49M | 983.42M | 1.36B |
R&D % of Revenue | 142.09% | 389.21% | 281.37% | 898.31% | 116.74% | 161.5% | 70.09% | 44.9% | 32.84% |
Other Operating Expenses | -5.81M | -8.86M | -15.56M | -22.18M | -40.02M | -31.63M | -35.5M | -54.16M | -75.91M |
Operating Income | -27.51M▲ 0% | -93.63M▼ 240.3% | -198.89M▼ 112.4% | -477.62M▼ 140.1% | -348.75M▲ 27.0% | -720.34M▼ 106.6% | -425.05M▲ 41.0% | -21.65M▲ 94.9% | 1.05B▲ 4970.3% |
Operating Margin % | -62.98% | -381.02% | -253.49% | -1158.06% | -70.13% | -175.37% | -34.66% | -0.99% | 25.39% |
Operating Income Growth % | -22.15% | -240.31% | -112.43% | -140.14% | 26.98% | -106.55% | 40.99% | 94.91% | 4970.3% |
EBITDA | -26.99M | -93.06M | -196.47M | -473.7M | -342.88M | -616M | -313.57M | -4.13M | 1.08B |
EBITDA Margin % | -61.78% | -378.72% | -250.4% | -1148.56% | -68.95% | -149.97% | -25.57% | -0.19% | 26.07% |
EBITDA Growth % | -21.73% | -244.8% | -111.11% | -141.11% | 27.62% | -79.65% | 49.1% | 98.68% | 26334.96% |
D&A (Non-Cash Add-back) | 521.87K | 563.94K | 2.42M | 3.92M | 5.87M | 104.34M | 111.48M | 17.53M | 28.1M |
EBIT | -32.97M | -93.63M | -175.78M | -604.95M | -398.65M | -727.12M | -303.59M | 87.64M | 1.28B |
Net Interest Income | 197.95K | 4.23M | 8.67M | 4.75M | 2.39M | 22.55M | 92.06M | 136.28M | 159.01M |
Interest Income | 197.95K | 4.23M | 8.8M | 5.15M | 3.48M | 24.74M | 92.96M | 138.5M | 163.09M |
Interest Expense | 0 | 0 | 139K | 403.66K | 1.1M | 2.19M | 904K | 2.22M | 4.08M |
Other Income/Expense | -5.46M | 18.3M | 22.97M | -127.73M | -51M | -8.97M | 120.55M | 106.83M | 223.99M |
Pretax Income | -32.97M▲ 0% | -75.32M▼ 128.5% | -175.92M▼ 133.6% | -605.35M▼ 244.1% | -399.74M▲ 34.0% | -729.31M▼ 82.4% | -304.5M▲ 58.2% | 85.18M▲ 128.0% | 1.28B▲ 1401.1% |
Pretax Margin % | -75.46% | -306.53% | -224.21% | -1467.77% | -80.39% | -177.56% | -24.83% | 3.89% | 30.78% |
Income Tax | 716.22K | 908.26K | 5.29M | 3.1M | 8.52M | -19.72M | -9.44M | -747.86M | -13.43M |
Effective Tax Rate % | -2.17% | -1.21% | -3.01% | -0.51% | -2.13% | 2.7% | 3.1% | -877.98% | -1.05% |
Net Income | -33.68M▲ 0% | -76.23M▼ 126.3% | -181.21M▼ 137.7% | -608.46M▼ 235.8% | -407.63M▲ 33.0% | -709.59M▼ 74.1% | -295.05M▲ 58.4% | 833.04M▲ 382.3% | 1.29B▲ 55.1% |
Net Margin % | -77.1% | -310.22% | -230.95% | -1475.29% | -81.97% | -172.76% | -24.06% | 38.03% | 31.11% |
Net Income Growth % | -49.84% | -126.32% | -137.71% | -235.78% | 33.01% | -74.08% | 58.42% | 382.34% | 55.1% |
Net Income (Continuing) | -33.68M | -76.23M | -181.21M | -608.46M | -408.26M | -709.59M | -295.05M | 833.04M | 1.29B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.37▲ 0% | -2.12▼ 54.7% | -4.69▼ 121.2% | -13.40▼ 185.7% | -7.99▲ 40.4% | -13.05▼ 63.3% | -5.16▲ 60.5% | 12.78▲ 347.7% | 19.63▲ 53.6% |
EPS Growth % | -14.17% | -54.74% | -121.23% | -185.71% | 40.37% | -63.33% | 60.46% | 347.67% | 53.6% |
EPS (Basic) | -1.37 | -2.12 | -4.69 | -13.40 | -7.99 | -13.05 | -5.16 | 13.92 | 21.14 |
Diluted Shares Outstanding | 24.61M | 35.98M | 38.62M | 45.41M | 51.08M | 54.38M | 57.17M | 65.18M | 66.03M |
Basic Shares Outstanding | 24.61M | 35.98M | 38.62M | 45.41M | 51.08M | 54.38M | 57.17M | 59.86M | 61.3M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ARGX Balance Sheet
argenx SE (ARGX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 440.06M | 654.82M | 1.54B | 2.06B | 2.54B | 2.77B | 4.12B | 4.88B | 6.9B |
Cash & Short-Term Investments | 431.62M | 645.81M | 1.5B | 2B | 2.34B | 2.19B | 3.18B | 3.38B | 4.44B |
Cash Only | 228.98M | 321.48M | 372.16M | 1.22B | 1.33B | 800.74M | 2.05B | 1.5B | 3.49B |
Short-Term Investments | 202.64M | 324.33M | 1.13B | 779.65M | 1B | 1.39B | 1.13B | 1.88B | 948.75M |
Accounts Receivable | 845K | 4.36M | 36.17M | 7.44M | 38.22M | 277.27M | 499.27M | 909.1M | 1.66B |
Days Sales Outstanding | 7.06 | 64.71 | 168.26 | 65.85 | 28.05 | 246.39 | 148.6 | 151.5 | 145.62 |
Inventory | 0 | 0 | 0 | 25.2M | 109.08M | 228.35M | 310.55M | 407.23M | 473.53M |
Days Inventory Outstanding | - | - | - | - | - | 2.83K | 961.94 | 653.97 | 383.52 |
Other Current Assets | 3.85M | 2.31M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 4.92M | 6.88M | 67.54M | 222.41M | 307.3M | 360.06M | 418.72M | 1.32B | 1.78B |
Property, Plant & Equipment | 811K | 942.58K | 9.18M | 11.58M | 15.84M | 16.23M | 22.68M | 43.52M | 48.25M |
Fixed Asset Turnover | 53.87x | 26.07x | 8.55x | 3.56x | 31.39x | 25.30x | 54.08x | 50.33x | 86.09x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 15.6K | 64.06K | 45.12M | 167.34M | 171.68M | 174.9M | 125.23M | 181.44M | 272.1M |
Long-Term Investments | 1.2K | 1.14K | 2.92M | 6.31M | 53.17M | 40.48M | 47.16M | 49.7M | 89.59M |
Other Non-Current Assets | 4.1M | 5.87M | 10.33M | 22.14M | 34.42M | 49.23M | 126.45M | 120.46M | 77.8M |
Total Assets | 444.98M▲ 0% | 661.7M▲ 48.7% | 1.61B▲ 143.3% | 2.28B▲ 41.6% | 2.85B▲ 25.0% | 3.13B▲ 10.0% | 4.54B▲ 44.9% | 6.2B▲ 36.5% | 8.68B▲ 40.0% |
Asset Turnover | 0.10x | 0.04x | 0.05x | 0.02x | 0.17x | 0.13x | 0.27x | 0.35x | 0.48x |
Asset Growth % | 300.01% | 48.7% | 143.35% | 41.56% | 25.04% | 9.96% | 44.93% | 36.55% | 39.99% |
Total Current Liabilities | 29.41M | 45.82M | 179.7M | 328.49M | 301.24M | 302.28M | 422.99M | 669.92M | 1.32B |
Accounts Payable | 5.28M | 6.87M | 10.51M | 206.32M | 208.85M | 188.72M | 245.56M | 342.23M | 1.27B |
Days Payables Outstanding | - | - | - | - | - | 2.34K | 760.63 | 549.58 | 1.03K |
Short-Term Debt | 0 | 0 | 2.22M | 3.48M | 3.51M | 3.42M | 4.65M | 6.53M | 10.83M |
Deferred Revenue (Current) | 16.95M | 23.21M | 136.28M | 46.33M | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 828K | 22.62M | 73.35M | 156.95M | -212.34M |
Current Ratio | 14.96x | 14.29x | 8.58x | 6.26x | 8.44x | 9.18x | 9.75x | 7.29x | 5.23x |
Quick Ratio | 14.96x | 14.29x | 8.58x | 6.19x | 8.08x | 8.42x | 9.01x | 6.68x | 4.87x |
Cash Conversion Cycle | - | - | - | - | - | 737.91 | 349.92 | 255.89 | -497.14 |
Total Non-Current Liabilities | 1.75M | 8.01K | 250.11M | 276.86M | 14.81M | 18.29M | 21.96M | 34.32M | 39.42M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36.33M |
Capital Lease Obligations | 0 | 0 | 5.1M | 6.18M | 7.96M | 9.01M | 15.35M | 32.52M | 36.33M |
Deferred Tax Liabilities | 0 | 0 | 0 | 1.49M | 6.44M | 8.41M | 5.16M | 0 | 0 |
Other Non-Current Liabilities | 1.75M | 8.01K | 72K | 156K | 417K | 870K | 1.45M | 1.8M | -33.23M |
Total Liabilities | 31.16M | 45.83M | 429.81M | 605.36M | 316.05M | 320.56M | 444.95M | 704.24M | 1.36B |
Total Debt | 0 | 0 | 7.32M | 9.66M | 11.46M | 12.43M | 20M | 39.05M | 83.49M |
Net Debt | -228.98M | -321.48M | -364.84M | -1.2B | -1.32B | -788.31M | -2.03B | -1.46B | -3.41B |
Debt / Equity | - | - | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 0.08x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -3.15x |
Interest Coverage | - | - | -1264.60x | -1498.68x | -363.73x | -331.56x | -335.83x | 39.50x | 314.23x |
Total Equity | 413.81M▲ 0% | 615.87M▲ 48.8% | 1.18B▲ 91.7% | 1.67B▲ 41.8% | 2.53B▲ 51.4% | 2.81B▲ 11.0% | 4.1B▲ 45.6% | 5.5B▲ 34.2% | 7.32B▲ 33.2% |
Equity Growth % | 520.87% | 48.83% | 91.66% | 41.82% | 51.38% | 11.03% | 45.63% | 34.19% | 33.19% |
Book Value per Share | 16.81 | 17.12 | 30.57 | 36.87 | 49.62 | 51.74 | 71.67 | 84.36 | 110.91 |
Total Shareholders' Equity | 413.81M | 615.87M | 1.18B | 1.67B | 2.53B | 2.81B | 4.1B | 5.5B | 7.32B |
Common Stock | 3.86M | 4.12M | 5.21M | 5.74M | 6.23M | 6.64M | 6.39M | 6.98M | 7.35M |
Retained Earnings | -120.65M | -194.01M | -383.48M | -991.93M | -1.4B | -2.11B | -2.4B | -1.57B | -279.77M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 14.11M | 35.4M | 53.04M | 321.21M | 465.41M | 71.72M | 72.07M | 66.71M | 73.59M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARGX Cash Flow Statement
argenx SE (ARGX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -43.84M | -61.59M | 151.63M | -398.46M | -606.81M | -862.81M | -420.33M | -82.75M | 850.49M |
Operating CF Margin % | -100.36% | -250.63% | 193.25% | -966.13% | -122.03% | -210.06% | -34.28% | -3.78% | 20.48% |
Operating CF Growth % | -493.33% | -40.47% | 346.2% | -362.79% | -52.29% | -42.19% | 51.28% | 80.31% | 1127.81% |
Net Income | -27.51M | -93.63M | -198.89M | -477.62M | -348.75M | -720.34M | -425.05M | 833.04M | 1.3B |
Depreciation & Amortization | 521.87K | 563.94K | 2.42M | 3.92M | 4.96M | 104.34M | 111.31M | 17.53M | 0 |
Stock-Based Compensation | 5.12M | 21.94M | 44.24M | 96.93M | 179.37M | 157.03M | 232.97M | 235.18M | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 42.13K | -666.94K | -6.17M | 6.68M | -101.44M | -27.91M | -30.67M | -843.89M | -21.61M |
Working Capital Changes | -22.02M | 10.2M | 310.03M | -28.38M | -340.95M | -375.93M | -308.89M | -324.6M | -423.94M |
Change in Receivables | -146K | -50.33K | -25.71M | 21.96M | -31.63M | -222.26M | -185.69M | -422.36M | -804.81M |
Change in Inventory | 0 | 0 | 0 | -23.85M | -83.88M | -119.28M | -83.03M | -95.83M | -99.26M |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 245.9M | 614.22M |
Cash from Investing | -194.41M | -123.02M | -833.27M | 344.69M | -347.07M | -461.18M | 308.21M | -717.59M | 823.88M |
Capital Expenditures | -414K | -712K | -1.8M | -1.07M | -3.62M | -837K | -812K | -1.8M | -112.03M |
CapEx % of Revenue | 0.95% | 2.9% | 2.29% | 2.59% | 0.73% | 0.2% | 0.07% | 0.08% | 2.7% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -2M | -13M | -7M | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -194M | -122.31M | -831.47M | 345.76M | -115.21M | -89.84M | 49.75M | 45.15M | 0 |
Cash from Financing | 366.35M | 279.88M | 733.73M | 833M | 1.12B | 843.76M | 1.34B | 279.76M | 233.73M |
Debt Issued (Net) | 0 | 0 | -1.51M | -2.55M | -3.85M | -4.17M | -3.8M | -7.64M | 0 |
Equity Issued (Net) | 393.14M | 292.52M | 755.64M | 813.19M | 1.09B | 760.95M | 1.2B | 308.72M | 279.24M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -26.8M | -12.64M | -20.4M | 22.37M | 32.12M | 86.97M | 143.8M | -21.32M | -45.51M |
Net Change in Cash | 121.13M▲ 0% | 103.15M▼ 14.8% | 50.37M▼ 51.2% | 844.64M▲ 1576.8% | 117.87M▼ 86.0% | -533.94M▼ 553.0% | 1.25B▲ 333.8% | -548.91M▼ 144.0% | 1.99B▲ 462.8% |
Free Cash Flow | -44.27M▲ 0% | -62.37M▼ 40.9% | 104.89M▲ 268.2% | -403.6M▼ 484.8% | -728.25M▼ 80.4% | -966.63M▼ 32.7% | -464.14M▲ 52.0% | -151.05M▲ 67.5% | 844.3M▲ 659.0% |
FCF Margin % | -101.32% | -253.81% | 133.69% | -978.6% | -146.45% | -235.33% | -37.85% | -6.9% | 20.33% |
FCF Growth % | -532.23% | -40.9% | 268.18% | -484.77% | -80.44% | -32.73% | 51.98% | 67.46% | 658.96% |
FCF per Share | -1.80 | -1.73 | 2.72 | -8.89 | -14.26 | -17.78 | -8.12 | -2.32 | 12.79 |
FCF Conversion (FCF/Net Income) | 1.30x | 0.81x | -0.84x | 0.65x | 1.49x | 1.22x | 1.42x | -0.10x | 0.66x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 378.4K | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARGX Key Ratios
argenx SE (ARGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -41.86% | -14.02% | -14.81% | -20.18% | -42.63% | -19.37% | -26.54% | -8.54% | 17.36% | 20.15% |
Return on Invested Capital (ROIC) | - | -26.3% | -29.31% | -26.88% | -55.86% | -31.18% | -33.39% | -15.57% | -0.53% | 19.89% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 92.83% | 90.39% | 89.62% | 89.15% |
Net Margin | -145.27% | -77.1% | -310.22% | -230.95% | -1475.29% | -81.97% | -172.76% | -24.06% | 38.03% | 31.11% |
Debt / Equity | - | - | - | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x |
Interest Coverage | - | - | - | -1264.60x | -1498.68x | -363.73x | -331.56x | -335.83x | 39.50x | 314.23x |
FCF Conversion | -0.50x | 1.30x | 0.81x | -0.84x | 0.65x | 1.49x | 1.22x | 1.42x | -0.10x | 0.66x |
Revenue Growth | 106.51% | 182.33% | -43.75% | 219.3% | -47.44% | 1105.72% | -17.4% | 198.56% | 78.6% | 89.64% |
Related:ARGX Dividend History·ARGX Revenue History·ARGX Price History·ARGX P/E History·ARGX Financial Ratios·ARGX Institutional Holders
ARGX Frequently Asked Questions
argenx SE (ARGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
argenx SE (ARGX) reported $4.49B in revenue for fiscal year 2025. This represents a 308142% increase from $1.5M in 2011.
argenx SE (ARGX) grew revenue by 89.6% over the past year. This is strong growth.
Yes, argenx SE (ARGX) is profitable, generating $1.44B in net income for fiscal year 2025 (31.1% net margin).
Dividend & Returns
argenx SE (ARGX) has a return on equity (ROE) of 20.2%. This is excellent, indicating efficient use of shareholder capital.
argenx SE (ARGX) generated $755.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.